Teva’s New Global Specialty Medicines Unit To Be Led By Koremans

Brought in from Sanofi in 2012 as president and CEO of Teva Europe, Rob Koremans now will head a new Global Specialty Medicines unit that CEO Jeremy Levin expects to complement Teva’s generics business. Levin spoke of establishing a “single, differentiated Teva presence” in each market through the two units working together.